Sagimet Biosciences Inc.
NASDAQ:SGMTBiotechnology
+$0.09 today
- Market cap
- $711.15M
- Beta
- 3.44
- P/E (TTM)
- -5.0
- EPS (TTM)
- -$1.34
Volume 0.93M
Average 1.49M
SGMT Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Sagimet Biosciences Inc.NASDAQ: SGMT
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt remains negative
Q1 FY2026 net debt was -$36.59M, compared with -$64.68M a year earlier.
Context
- Net debt amounted to 34.0% of total assets at the end of Q1 FY2026, down 10.3 pp from a year earlier.
- Net debt increased in 1 of the last 3 fiscal years.
What to watch
Whether net debt keeps rising in the next quarterly balance sheet after a +43.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (34.94M) USD
- Year-over-year change
- +53.9%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (34.94M) | +53.9% |
| FY2024 | 2024-12-31 | (75.76M) | -0.9% |
| FY2023 | 2023-12-31 | (75.07M) | -141749.1% |
| FY2022 | 2022-12-31 | 53K | +100.1% |
| FY2021 | 2021-12-31 | (56.38M) | — |
Net Debt vs competitors
How SGMT compares with its peers on the latest reported figures
- SGMT's Mar 2026 net debt of -$36.59M is the 7th highest of the 11 companies compared; the peer median is -$27.66M.
- Its year-over-year change of +43.4% is the 4th highest of 11, against a peer median of -19.9%.
- Net debt amounts to 34.0% of total assets for SGMT, versus a peer median of 18.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $3.68B | +11687.6% | — | 1.7% | |
| Mar 2026 | $17.36M | +136.9% | — | 15.7% | |
| Mar 2026 | -$8.75M | +73.3% | — | 4.0% | |
| Mar 2026 | -$13.13M | -329.5% | — | 39.6% | |
| Mar 2026 | -$26.69M | -146.3% | — | 8.0% | |
| Mar 2026 | -$28.63M | -40.4% | — | 12.2% | |
SGMTSagimet Biosciences Inc. | Mar 2026 | -$36.59M | +43.4% | — | 34.0% |
| Mar 2026 | -$46.92M | -79.3% | — | 21.1% | |
| Mar 2026 | -$78.68M | +33.3% | — | 29.5% | |
| Mar 2026 | -$187.39M | -7.5% | — | 76.4% | |
ZURAZura Bio Limited | Mar 2026 | -$225.59M | -32.3% | — | 98.7% |
| Peer median (excluding SGMT) | -$27.66M | -19.9% | — | 18.4% | |
Competitors are the stored peer set for SGMT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Sagimet Biosciences Inc.
NASDAQ:SGMT
Intrinsic Alpha fair value
Locked
Current Price
$10.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.